NYCELSIO Trademark

Trademark Overview

On Friday, April 25, 2025, a trademark application was filed for NYCELSIO with the United States Patent and Trademark Office. The USPTO has given the NYCELSIO trademark a serial number of 99155730. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Friday, April 25, 2025. This trademark is owned by Adaptimmune Limited. The NYCELSIO trademark is filed in the Pharmaceutical Products and Medical & Beauty Services & Agricultural Services categories with the following description:

Cell therapy pharmaceutical preparations; immunotherapy preparations; T-cell receptors; immunotherapy preparations comprising engineered T-cell receptors; immunotherapy preparations comprising genes encoding engineered T-cell receptors

Cell therapy medical treatment services; immunotherapy services; medical treatment and immune-therapy comprising harvesting a patient’s white blood cells, combining white blood cells with an engineered T-cell receptor therapeutic, transducing the white blood cells with the gene encoding the engineered T-cell receptor and infusion of the transduced white blood cells back into the patient
nycelsio

General Information

Serial Number99155730
Word MarkNYCELSIO
Filing DateFriday, April 25, 2025
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateFriday, April 25, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesCell therapy pharmaceutical preparations; immunotherapy preparations; T-cell receptors; immunotherapy preparations comprising engineered T-cell receptors; immunotherapy preparations comprising genes encoding engineered T-cell receptors
Goods and ServicesCell therapy medical treatment services; immunotherapy services; medical treatment and immune-therapy comprising harvesting a patient’s white blood cells, combining white blood cells with an engineered T-cell receptor therapeutic, transducing the white blood cells with the gene encoding the engineered T-cell receptor and infusion of the transduced white blood cells back into the patient

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, April 25, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, April 25, 2025
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAdaptimmune Limited
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressOxford OX14 4RX
GB

Trademark Events

Event DateEvent Description
Friday, April 25, 2025NEW APPLICATION ENTERED
Friday, April 25, 2025APPLICATION FILING RECEIPT MAILED
Wednesday, April 30, 2025TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Wednesday, April 30, 2025TEAS VOLUNTARY AMENDMENT RECEIVED

Related Keywords

nycelsio cell cells immunotherapy preparations white blood engineered receptors therapy comprising